Equities research analysts predict that Neos Therapeutics, Inc. (NASDAQ:NEOS) will announce ($0.83) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Neos Therapeutics’ earnings. The lowest EPS estimate is ($0.91) and the highest is ($0.74). Neos Therapeutics reported earnings of ($1.58) per share in the same quarter last year, which suggests a positive year over year growth rate of 47.5%. The business is expected to report its next earnings results on Thursday, August 10th.

On average, analysts expect that Neos Therapeutics will report full-year earnings of ($3.17) per share for the current year, with EPS estimates ranging from ($3.55) to ($2.79). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.33) per share, with EPS estimates ranging from ($2.15) to ($0.51). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Neos Therapeutics.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings data on Tuesday, May 9th. The company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.07. The firm had revenue of $5.63 million during the quarter. Neos Therapeutics had a negative net margin of 719.86% and a negative return on equity of 512.10%.

Several research firms have recently issued reports on NEOS. Zacks Investment Research upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating and set a $8.75 target price for the company in a report on Wednesday, May 17th. BMO Capital Markets restated an “outperform” rating and issued a $15.00 target price on shares of Neos Therapeutics in a report on Saturday, March 11th. Cowen and Company began coverage on shares of Neos Therapeutics in a report on Wednesday, April 5th. They issued an “outperform” rating and a $20.00 target price for the company. Finally, ValuEngine upgraded shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Tuesday.

COPYRIGHT VIOLATION NOTICE: “Neos Therapeutics, Inc. (NEOS) Expected to Post Earnings of -$0.83 Per Share” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/06/23/neos-therapeutics-inc-neos-expected-to-post-earnings-of-0-83-per-share.html.

Several large investors have recently added to or reduced their stakes in NEOS. UBS Group AG raised its stake in Neos Therapeutics by 6.1% in the first quarter. UBS Group AG now owns 108,714 shares of the company’s stock valued at $783,000 after buying an additional 6,276 shares during the period. Geode Capital Management LLC raised its stake in Neos Therapeutics by 20.7% in the first quarter. Geode Capital Management LLC now owns 92,956 shares of the company’s stock valued at $669,000 after buying an additional 15,962 shares during the period. Vanguard Group Inc. raised its stake in Neos Therapeutics by 215.1% in the first quarter. Vanguard Group Inc. now owns 588,994 shares of the company’s stock valued at $4,241,000 after buying an additional 402,058 shares during the period. Mission Wealth Management LLC purchased a new stake in Neos Therapeutics during the first quarter valued at about $122,000. Finally, Teachers Advisors LLC raised its stake in Neos Therapeutics by 16.3% in the first quarter. Teachers Advisors LLC now owns 29,663 shares of the company’s stock valued at $214,000 after buying an additional 4,167 shares during the period. Hedge funds and other institutional investors own 40.16% of the company’s stock.

Shares of Neos Therapeutics (NASDAQ NEOS) traded down 2.03% during trading on Friday, hitting $7.25. 1,193,557 shares of the stock traded hands. The stock’s market cap is $163.56 million. Neos Therapeutics has a 12 month low of $4.85 and a 12 month high of $9.99. The firm’s 50-day moving average price is $7.87 and its 200-day moving average price is $6.82.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get a free copy of the Zacks research report on Neos Therapeutics (NEOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.